Inventor
JR., DAVID JOHN MORGANS
Inventor
US
Overview
Patents· 8 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations30%
C07DHeterocyclic compounds30%
A61KPreparations for medical, dental or toiletry purposes26%
C07BGeneral methods of organic chemistry7%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium7%
PatentTitleYear
12,534,453Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof2026RE050554Amino acid compounds and methods of use202512,344,610APOL1 inhibitors and methods of use202511,976,067APOL1 inhibitors and methods of use202411,814,367Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof202311,673,887N-acyl amino acid compounds and methods of use202311,634,418Amino acid compounds and methods of use202311,560,376Amino acid compounds and methods of use2023Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2023–2026Patents assigned to MAZE THERAPEUTICS INC (4)· patent assignee history
2023–2025Patents assigned to PLIANT THERAPEUTICS INC (4)· patent assignee history
2023–2026Based in US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| MAZE THERAPEUTICS INC | 4 | 2023–2026 |
| PLIANT THERAPEUTICS INC | 4 | 2023–2025 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 8 | 2023–2026 |